Mochida Pharmaceutical Co., Ltd. (4534) AI Stock Analysis

• Market Cap: ¥123.01B
• Dividend Yield: 2.34%
• Average Volume (3M): 34.37K
• Price to Earnings (P/E): 19.1
• Beta (1Y): 0.55
• Revenue Growth: 4.35%
• EPS Growth: 48.30%
• Country: JP
• Employees: 1,522
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 55.36
• Shares Outstanding: 36,390,000
• 10 Day Avg. Volume: 38,620
• 30 Day Avg. Volume: 34,366
• PEG Ratio: 0.75
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 1.07
• P/FCF Ratio: 15.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: ¥3,626.00 ▲(0.30% Upside)

Mochida Pharmaceutical's strong financial stability and profitability are key strengths, supported by positive technical momentum. However, challenges in revenue growth and cash flow volatility, along with a moderate valuation, limit the overall score. The absence of earnings call insights and corporate events does not impact the evaluation.

Positive Factors

Financial Stability

Mochida's low leverage and strong equity base provide financial stability, reducing risk and enhancing its ability to invest in growth opportunities.

Profitability

Maintaining healthy profit margins suggests effective cost control and operational efficiency, supporting long-term profitability and competitive positioning.

Cash Generation

Strong cash generation relative to earnings enhances financial flexibility, enabling strategic investments and shareholder returns.

Negative Factors

Revenue Growth Challenges

Declining revenue growth indicates potential challenges in market expansion and product adoption, which could impact future earnings.

Cash Flow Volatility

Volatile cash flow growth can affect the company's ability to fund operations and investments, posing risks to financial stability.

Declining Return on Equity

A declining return on equity may indicate reduced efficiency in using equity to generate profits, potentially impacting investor confidence.

Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Mochida Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which include both proprietary drugs and generic medicines. The company earns money by marketing its innovative drugs in Japan and international markets, often focusing on niche therapeutic areas where there is unmet medical need. Key revenue streams include sales from hospital and retail pharmacies, as well as international licensing agreements and partnerships with other pharmaceutical firms for co-development and distribution of products. Additionally, Mochida may benefit from patent protections on its proprietary medications, allowing it to maintain higher prices before generic competition enters the market. Strategic collaborations with research institutions and other companies further enhance its product pipeline and market reach, contributing to its overall earnings.

Mochida Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Mochida Pharmaceutical demonstrates strong profitability and financial stability with low leverage. However, declining revenue growth and volatile cash flow trends pose challenges. The company needs to address these areas to sustain long-term growth and improve financial performance.

Income Statement

Mochida Pharmaceutical has shown a decline in revenue growth over the past few years, with a significant drop in the most recent year. Despite this, the company maintains healthy gross and net profit margins, indicating strong cost management and profitability. However, the declining revenue trend is a concern for future growth prospects.

Balance Sheet

The company has a very low debt-to-equity ratio, reflecting minimal leverage and a strong equity base. Return on equity has been stable, though slightly declining, indicating efficient use of equity to generate profits. The equity ratio is robust, suggesting financial stability and low risk.

Cash Flow

Mochida Pharmaceutical's cash flow performance is mixed. While the operating cash flow has improved recently, the free cash flow growth has been volatile. The free cash flow to net income ratio is strong, indicating good cash generation relative to earnings, but past negative free cash flow growth rates highlight potential cash flow management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	106.38B	105.16B	102.89B	103.26B	110.18B	103.00B
Gross Profit	54.46B	53.79B	52.07B	55.12B	59.55B	54.79B
EBITDA	11.20B	11.00B	8.97B	11.71B	17.28B	14.75B
Net Income	6.03B	5.68B	4.55B	6.65B	10.57B	8.59B
Balance Sheet
Total Assets	161.74B	160.12B	158.80B	158.83B	163.14B	161.79B
Cash, Cash Equivalents and Short-Term Investments	54.69B	51.15B	46.79B	60.51B	61.91B	63.49B
Total Debt	830.00M	342.00M	369.00M	190.00M	0.00	0.00
Total Liabilities	30.59B	29.43B	30.83B	32.06B	34.50B	34.82B
Stockholders Equity	131.15B	130.69B	127.97B	126.77B	128.64B	126.97B
Cash Flow
Free Cash Flow	0.00	7.19B	-9.78B	5.13B	4.36B	7.11B
Operating Cash Flow	0.00	9.35B	-7.48B	7.30B	7.46B	9.20B
Investing Cash Flow	0.00	17.36B	74.00M	-2.95B	-2.01B	-880.00M
Financing Cash Flow	0.00	-2.87B	-6.39B	-6.88B	-5.96B	-5.11B

Mochida Pharmaceutical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3615.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Positive. The current price of 3615 is above the 20-day moving average (MA) of 3487.50, above the 50-day MA of 3344.50, and above the 200-day MA of 3117.54, indicating a bullish trend. The MACD of 74.68 indicates Negative momentum. The RSI at 65.17 is Neutral, neither overbought nor oversold. The STOCH value of 79.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4534.

Mochida Pharmaceutical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4553	81 Outperform	¥178.16B	8.63	11.81%	2.14%	9.32%	30.85%
4521	80 Outperform	¥147.68B	215.05	0.44%	4.16%	-5.99%	-96.04%
4534	73 Outperform	¥123.01B	19.08	5.11%	2.34%	4.35%	48.30%
4569	69 Neutral	¥84.17B	9.85	―	3.36%	11.65%	93.46%
4886	67 Neutral	¥55.91B	12.50	―	2.52%	5.44%	-20.33%
4547	66 Neutral	¥195.25B	13.97	6.57%	2.48%	13.11%	41.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Mochida Pharmaceutical Co., Ltd. Corporate Events

Mochida Pharmaceutical Reports Strong Financial Growth for H1 2025

Mochida Pharmaceutical Co., Ltd. reported a strong financial performance for the six months ending September 30, 2025, with net sales increasing by 7.6% and operating profit rising by 31% compared to the previous year. The company’s comprehensive income surged by 131.8%, reflecting robust growth and improved profitability, which may positively impact its market position and stakeholder confidence.

The most recent analyst rating on (JP:4534) stock is a Hold with a Yen3191.00 price target. To see the full list of analyst forecasts on Mochida Pharmaceutical Co., Ltd. stock, see the JP:4534 Stock Forecast page.